EUVIMEDEUVIMED entdecken
Crossref

Is Oncoplastic Surgery Safe in High‐Risk Breast Cancer Phenotypes?

Gabriel De La Cruz Ku, Carly Wareham, Caroline King, Akash Koul, Anshumi Desai, Sarah M Persing, Salvatore Nardello, Abhishek Chatterjee

Journal of Surgical Oncology · 2025-02 · 131 (2) · 133-142

DOI: 10.1002/jso.27899 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 16.09.2024. Verfasst von Gabriel De La Cruz Ku und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Universidad Cientifica del Sur, Lima, Peru. Hauptthemen laut MEDLINE: Breast Neoplasms, Mastectomy, Mammaplasty, Mastectomy, Segmental. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oncoplastic surgery (OPS) has increased in popularity over the recent years. It is a form of breast conservation surgery allowing for larger partial mastectomy (PM) resections followed by either volume displacement or volume replacement reconstruction techniques. However, there is a lack of evidence on the effectiveness and safety of OPS with radiotherapy (OPS + RT) in high‐risk breast cancer phenotypes, such as triple negative breast cancer (TNBC) and HER2 positive (HER2+) patients. Our aim was to compare the breast cancer‐specific survival (BCSS) and postoperative surgical complications in OPS + RT compared to PM alone with radiation (PM + RT) and total mastectomy (MTX) without radiotherapy (MTX‐RT).

Methods

Patient data were analyzed from the Surveillance, Epidemiology, and End Results (SEER) cancer registries from January 1, 2012 to December 31, 2020. Patients were stratified according to the type of surgery. Cox regression analysis was performed to assess prognostic factors of BCSS.

Results

A total of 24 621 patients with high‐risk breast cancer phenotypes were identified, 180 underwent OPS + RT; 13 402, PM + RT; and 11 039 MTX‐RT. OPS + RT was more frequently performed in younger (mean age of 65.53 years, SD: 9.29, p < 0.001), non‐Hispanic White (90.5% vs. 77.7% vs. 76.3%) and single women (17.9% vs. 12.1% vs. 13.3%). MTX‐RT was usually performed in patients with high histological grade, TNBC, and higher stages. Overall complication rates were higher in the MTX‐RT, compared to OPS + RT and PM + RT, 2%, 1.1%, and 0.7%, respectively, p < 0.001. Rates of hematoma and surgical site infections were higher in the MTX‐RT group. With a median follow‐up of 46 months, OPS + RT had better BCSS rates at 5 years compared to PM + RT and MTX‐RT (97.1% vs. 94.7% vs. 89.8%, p < 0.001). MTX‐RT was found to be an independent prognostic factor of worse BCSS compared to OPS + RT (hazard ratio [HR] = 2.584; 95% confidence interval [CI]: 1.005–7.171), while PM + RT had no difference compared to OPS + RT (HR = 1.670, 95% CI: 0.624–4.469).

Conclusions

OPS is a safe breast surgical option in patients with HER2+ and TNBC. Patients with high‐risk phenotypes who underwent OPS + RT and have similar BCSS and complication rates compared to standard breast surgical options. As such, OPS should be considered as an option whenever breast conservation surgery is being discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMastectomyMammaplastyMastectomy, SegmentalPostoperative ComplicationsTriple Negative Breast NeoplasmsHumansFemaleAgedMiddle AgedPhenotypeSurvival RateSEER ProgramPrognosisFollow-Up StudiesRadiotherapy, Adjuvant

Stichwörter der Autor:innen

breast cancer‐specific survivaloncoplastic surgeryoutcomes high‐risk phenotypespartial mastectomytotal mastectomy

Autor:innen und Institutionen

  • Department of Surgery, Universidad Cientifica del Sur, Lima, Peru.
  • Department of Surgery, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
  • Department of Surgery, Tufts Medical Center, Boston, Massachusetts, USA.
  • Department of Surgery, University of Miami Medical School, Miami, Florida, USA.
  • Division of Plastic and Reconstructive Surgery, Department of Surgery, Tufts Medical Center, Boston, Massachusetts, USA.
  • Division of Surgical Oncology, Department of Surgery, Tufts Medical Center, Boston, Massachusetts, USA.

Zitieren

APA

Ku, G. C., Wareham, C., King, C., Koul, A., Desai, A., Persing, S. M., Nardello, S., & Chatterjee, A. (2025). Is Oncoplastic Surgery Safe in High‐Risk Breast Cancer Phenotypes?. Journal of Surgical Oncology, 131(2), 133-142. https://doi.org/10.1002/jso.27899

Vancouver

Ku GC, Wareham C, King C, Koul A, Desai A, Persing SM, et al. Is Oncoplastic Surgery Safe in High‐Risk Breast Cancer Phenotypes?. Journal of Surgical Oncology. 2025;131(2):133-142. doi:10.1002/jso.27899

BibTeX
@article{Ku2025,
  author = {Ku, Gabriel De La Cruz and Wareham, Carly and King, Caroline and Koul, Akash and Desai, Anshumi and Persing, Sarah M and Nardello, Salvatore and Chatterjee, Abhishek},
  title = {Is Oncoplastic Surgery Safe in High‐Risk Breast Cancer Phenotypes?},
  journal = {Journal of Surgical Oncology},
  year = {2025},
  volume = {131},
  number = {2},
  pages = {133--142},
  doi = {10.1002/jso.27899}
}
Kostenlos starten →